Madrigal Pharmaceuticals, Inc.

NasdaqGS:MDGL Stock Report

Market Cap: US$6.1b

Madrigal Pharmaceuticals Future Growth

Future criteria checks 5/6

Madrigal Pharmaceuticals is forecast to grow earnings and revenue by 64.4% and 55.5% per annum respectively. EPS is expected to grow by 63.5% per annum. Return on equity is forecast to be -138.5% in 3 years.

Key information

64.4%

Earnings growth rate

63.5%

EPS growth rate

Biotechs earnings growth25.9%
Revenue growth rate55.5%
Future return on equity-138.5%
Analyst coverage

Good

Last updated23 Jul 2024

Recent future growth updates

Recent updates

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Jun 09

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Apr 24

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Feb 07

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Dec 20
Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Aug 05
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Buy And Hoard Before Q4 Data Readout

Aug 04

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Jul 08

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 11
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal: NASH Data In Q4 Is The Key

Apr 19

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Feb 24
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Jan 31

Madrigal: Powerful Catalyst Approaching

Jan 09

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Nov 08
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Jul 26
We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals: Leading The NASH Innovation

May 05

Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

Apr 12
Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth

Dec 28
We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth

Madrigal Pharma: A Look At The Early MAESTRO Trial Data

Nov 27

Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow

Nov 17

Madrigal Pharmaceuticals EPS misses by $0.40

Nov 05

Earnings and Revenue Growth Forecasts

NasdaqGS:MDGL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202697098-89-19413
12/31/2025364-405-361-48115
12/31/202475-584-492-56016
3/31/2024N/A-444-391-389N/A
12/31/2023N/A-374-326-324N/A
9/30/2023N/A-347-303-303N/A
6/30/2023N/A-330-277-277N/A
3/31/2023N/A-315-259-259N/A
12/31/2022N/A-295-225-225N/A
9/30/2022N/A-274-215-214N/A
6/30/2022N/A-256-201-201N/A
3/31/2022N/A-247-191-190N/A
12/31/2021N/A-242-184-184N/A
9/30/2021N/A-236-191-191N/A
6/30/2021N/A-231-193-193N/A
3/31/2021N/A-219-171-170N/A
12/31/2020N/A-202-158-158N/A
9/30/2020N/A-171-115-115N/A
6/30/2020N/A-134-79-78N/A
3/31/2020N/A-105-66-66N/A
12/31/2019N/A-84-42-42N/A
9/30/2019N/A-68-36-36N/A
6/30/2019N/A-55-30-30N/A
3/31/2019N/A-42-23-23N/A
12/31/2018N/A-33-26-26N/A
9/30/2018N/A-30-25-25N/A
6/30/2018N/A-30-25-25N/A
3/31/2018N/A-32-27-27N/A
12/31/2017N/A-31N/A-22N/A
9/30/2017N/A-30N/A-22N/A
6/30/2017N/A-36N/A-26N/A
3/31/2017N/A-31N/A-21N/A
12/31/2016N/A-26N/A-18N/A
9/30/2016N/A-21N/A-13N/A
6/30/2016N/A-8N/A-5N/A
3/31/2016N/A-7N/A-3N/A
12/31/2015N/A-7N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: MDGL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MDGL is expected to become profitable in the next 3 years.

Revenue vs Market: MDGL's revenue (55.5% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: MDGL's revenue (55.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MDGL is forecast to be unprofitable in 3 years.


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.